2014

Covance Reports Fourth Quarter Net Revenue Of $623 Million, Pro Forma EPS Of $0.87 And Adjusted Net Orders Of $769 Million -- Issues FY2014 Pro Forma EPS Target of $3.65 to $4.00 --

PRINCETON, N.J., Feb. 4, 2014 /PRNewswire/ -- Covance Inc. (NYSE: CVD) today reported results for its fourth quarter and year ended December 31, 2013. Net revenue in the fourth quarter was $623.1 million, representing 10.8% growth from the fourth quarter of 2012's GAAP result of $562.2 million, and 11.1% growth from the fourth quarter of 2012's pro forma result of $560.7 million. On a GAAP basis, the company reported earnings of $0.80 per diluted share in the fourth quarter of 2013 as compared to GAAP earnings of $0.61 in the fourth quarter of 2012. Excluding charges associated with restructuring, other cost reduction actions and other items in both periods, the company reported pro forma earnings per diluted share of $0.87, up 18.6% over the pro forma earnings of $0.73 for the fourth quarter of 2012.

On a full-year basis, net revenue in 2013 was $2.4 billion, representing 10.2% growth from 2012's GAAP result of $2.18 billion, and 10.6% growth from 2012's pro forma result of $2.17 billion. On a GAAP basis, the company reported earnings per diluted share of $3.15 in 2013 as compared to GAAP earnings of $1.68 in 2012. Excluding charges associated with restructuring, other cost reduction actions and other items in both periods, the company reported pro forma earnings per diluted share of $3.23 in 2013, up 19.6% over the pro forma earnings of $2.70 for 2012.

"In 2013, Covance continued to benefit from market share gains in central laboratories, strong operational delivery in clinical development, improving market conditions in toxicology, and successful execution of our on-going strategic IT projects. This performance enabled us to significantly exceed our 2013 financial targets, with a return to double-digit revenue growth, pro forma EPS of $3.23, and free cash flow in excess of $240 million. In addition, we delivered strong orders throughout the year, resulting in record adjusted net orders of $3 billion, and an adjusted net book-to-bill of 1.25 to 1 for the year," said Joe Herring, Chairman and Chief Executive Officer. "For the fourth quarter, revenue grew to $623 million, up 11.1% from 2012 pro forma revenue, and pro forma earnings per share grew 18.6% to $0.87. Adjusted net orders in the fourth quarter were $769 million, representing an adjusted net book-to-bill of 1.23 to 1.

"Late-Stage Development fourth quarter revenues grew 14.5% year-on-year to $395 million. This increase was led by 17% growth in central laboratories and 13% growth in clinical development. Late-Stage Development pro forma operating margins increased 140 basis points year-on-year and 10 basis points sequentially to 22.7%. In Early Development, revenue grew 5.7% year-on-year on a pro forma basis, led by growth in clinical pharmacology and toxicology. Sequentially, revenues grew $7.9 million from the third quarter, driven primarily by strong sequential growth in toxicology. Early Development fourth quarter pro forma operating margins of 12.1% were flat sequentially after normalizing for the UK R&D credits, as strength in toxicology was offset by normal seasonality in clinical pharmacology.

"Looking ahead to 2014, for the full year, we expect year-on-year revenue growth in the 6% to 10% range and pro forma diluted earnings per share, excluding costs from our ongoing restructuring activities, in the range of $3.65 to $4.00 (assuming foreign exchange rates remain at year-end 2013 levels). In the first quarter of 2014, we expect revenue to be up from the fourth quarter level and pro forma earnings per share to increase sequentially by a couple of cents, as we forecast an increase in Late-Stage Development net revenues and earnings to be partially off-set by seasonally-lower first quarter Early Development results." 

Consolidated Results

 

($ in millions except EPS)

4Q13

4Q12

Change

FY13

FY12

Change

Total Revenues

$669.8

$609.1


$2,595.1

$2,365.7


Less: Reimbursable Out-of-Pockets 

$46.7

$46.9


$192.8

$185.1


Net Revenues

$623.1

$562.2

10.8%

$2,402.3

$2,180.6

10.2%

Operating Income

$55.0

$43.1

27.5%

$217.3

$115.9

87.6%

   Operating Margin

8.8%

7.7%


9.0%

5.3%


Net Income

$45.8

$33.9

35.3%

$179.2

$94.7

89.2%

Diluted Earnings per Share

$0.80

$0.61

30.5%

$3.15

$1.68

87.2%

Revenue from Facilities Closed in 2012**

-

$1.5


-

$8.8


Net Revenue, continuing ops*

$623.1

$560.7

11.1%

$2,402.3

$2,171.9

10.6%

Restructuring Costs and Other Items

($9.8)

($6.6)


($26.8)

($73.1)


Loss from Facilities Closed in 2012**

-

($2.9)


-

($9.3)


Operating Income, excluding items*

$64.7

$52.5

23.2%

$244.2

$198.2

23.2%

  Operating Margin, excluding items*

10.4%

9.4%


10.2%

9.1%


Gain on Sale of Investments

-

-


$16.4

$1.5


Impairment of Equity Investment

-

-


-

($7.4)


Favorable Income Tax Developments

$3.0

-


$3.0

$11.5


Net Income, excluding items*

$49.6

$40.3

23.0%

$183.7

$151.9

20.9%

Diluted EPS, excluding items*

$0.87

$0.73

18.6%

$3.23

$2.70

19.6%

* See attached pro forma income statements for reconciliation of 2013 and 2012 GAAP to pro forma amounts.

** Facilities closed in 2012 include Chandler, Honolulu and Basel.

 

Operating Segment Results

Early Development

 

($ in millions)

4Q13

4Q12

Change

FY13

FY12

Change

Net Revenues

$228.3

$217.4

5.0%

$870.5

$869.5

0.1%

Operating Income

$21.9

$18.7

17.3%

$87.5

$4.0

2,087.6%

Operating Margin

9.6%

8.6%


10.1%

0.5%


Revenue from Facilities Closed in 2012**

-

$1.5


-

$8.8


Net Revenue, continuing ops

$228.3

$215.9

5.7%

$870.5

$860.8

1.1%

Restructuring Costs and Other Items

($5.7)

($4.3)


($13.2)

($69.5)


Loss from Facilities Closed in 2012**

-

($2.9)


-

($9.3)


Operating Income, excluding items

$27.6

$25.9

6.7%

$100.7

$82.7

21.7%

Operating Margin, excluding items

12.1%

12.0%


11.6%

9.6%


** Facilities closed in 2012 include Chandler, Honolulu and Basel.

 

The Early Development segment includes preclinical toxicology, analytical chemistry, clinical pharmacology, discovery support, and research products. Net revenues in the fourth quarter of 2013 were $228.3 million, compared to $217.4 million on a GAAP basis and $215.9 million on a pro forma basis in the fourth quarter of last year. Last year's pro forma revenue excluded $1.5 million in revenue from the three sites closed by the end of 2012. On a pro forma basis, net revenue increased 5.7%, including a 60 basis point foreign exchange tailwind, as continued strong growth in clinical pharmacology and improved results in toxicology were partially offset by declines in discovery support and certain pharmaceutical chemistry services. Sequential growth of $7.9 million was primarily driven by toxicology.

GAAP operating income in the fourth quarter of 2013 was $21.9 million, and included $0.8 million in costs associated with our previously-announced restructuring actions and $4.9 million in asset impairment charges relating to our Manassas and Basel properties, which are being marketed for sale. This compares to GAAP operating income of $18.7 million in the fourth quarter of 2012, which included restructuring costs of $4.3 million and losses at facilities closed in 2012 of $2.9 million. Pro forma operating income, excluding these costs, was $27.6 million in the fourth quarter of this year, a 6.7% increase from the $25.9 million reported in the fourth quarter of 2012 as growth in clinical pharmacology and toxicology and the shift to above margin treatment for the UK R&D credit more than offset declines in discovery support and certain chemistry services. Pro forma operating margins were 12.1% in the fourth quarter of 2013, versus 12.0% in the fourth quarter of 2012 and 13.1% last quarter. Third quarter 2013 margins included a six month impact of the shift to above margin treatment of the UK R&D credit (as the law was signed in July 2013, but applied retroactive to April 1, 2013) versus only a three month impact in the current quarter. 

On January 31, 2014, Covance sold its high-complexity genomics laboratory, located in Seattle, Washington, to Laboratory Corporation of America Holdings, and entered into a five year services agreement, pursuant to which Covance will collaborate with LabCorp to continue to offer these services to its clients. Covance expects to report a small gain on this sale in its first quarter ending March 31, 2014, which will be excluded from its pro forma earnings per share. Covance will continue to provide other genomics services to its clients through its central laboratories. 

Late-Stage Development

               

($ in millions)

4Q13

4Q12

Change

FY13

FY12

Change

Net Revenues

$394.8

$344.8

14.5%

$1,531.8

$1,311.1

16.8%

Operating Income

$89.2

$72.7

22.8%

$338.5

$277.6

22.0%

Operating Margin

22.6%

21.1%


22.1%

21.2%


Restructuring Costs

($0.3)

($0.7)


($4.1)

($1.3)


Operating Income, excluding items

$89.5

$73.4

22.0%

$342.6

$278.8

22.9%

Operating Margin, excluding items

22.7%

21.3%


22.4%

21.3%


 

The Late-Stage Development segment includes central laboratory, Phase IIb-IV clinical development, and market access services. Net revenues for the fourth quarter of 2013 grew 14.5% year-on-year to $394.8 million, and increased $8.5 million sequentially from the third quarter level. In the quarter, foreign exchange favorably impacted revenue growth by 170 basis points. Year-over-year growth was driven by increases of 17% in central laboratories and 13% in clinical development, while the sequential revenue increase was led by growth in clinical development followed by growth in central laboratories. 

Operating income for the fourth quarter was $89.2 million on a GAAP basis and included $0.3 million in costs associated with our ongoing restructuring actions. On a pro forma basis, operating income was $89.5 million, up 22.0% year-over-year. Pro Forma operating income also increased $2.1 million sequentially. Pro forma operating margins were 22.7% in the fourth quarter of 2013, versus 21.3% in the fourth quarter of 2012 and 22.6% last quarter. The year-on-year increase in profitability was driven by operating leverage in both clinical development and central laboratories, partially offset by increased spending on strategic IT projects. On a sequential basis, operating margins increased 10 basis points overcoming a headwind from the normalization of the UK R&D credit and increased IT spending due primarily to margin expansion in clinical development. 

Corporate Information

The company reported fourth quarter adjusted net orders of $769 million. Backlog at December 31, 2013 grew to $6.92 billion compared to $6.83 billion at September 30, 2013 and $6.64 billion at December 31, 2012. Foreign exchange contributed $36 million to backlog growth on a sequential basis. 

Corporate expenses totaled $56.2 million in the fourth quarter of 2013 (including $3.8 million in restructuring costs) compared to $51.4 million last quarter (including $2.8 million in restructuring costs) and $48.3 million in the fourth quarter of 2012 (including $1.5 million in restructuring costs). The largest driver of the year-over-year and sequential increases in corporate expenses are spending on our strategic IT initiatives followed by higher incentive compensation expenses related to stronger-than-budgeted business performance. 

Cash, cash equivalents and short-term investments at December 31, 2013 were $729 million compared to $593 million at September 30, 2013 and $493 million at December 31, 2012. During the fourth quarter, the company raised $250 million from the issuance of senior notes. Proceeds from these notes and cash from operations were used to fully repay the $265 million outstanding balance on the revolving credit facility. The revolving credit facility will be maintained to provide flexibility to execute our growth strategy over the long-term.                                                      

Net Days Sales Outstanding (DSO) declined one day in the fourth quarter to 34 days at December 31, 2013 compared to 35 days at September 30, 2013 and 36 days at December 31, 2012. 

Free cash flow (defined as operating cash flow less capital expenditures) for the fourth quarter of 2013 was $134 million, consisting of operating cash flow of $193 million less capital expenditures of $58 million. Free cash flow for the year was $243 million, consisting of operating cash flow of $406 million less capital expenditures of $162 million. Free cash flow in both the fourth quarter and full year of 2013 include a client payment of approximately $28 million for Value Added Tax, which had been pending resolution between the client and the tax authorities during the year. Following resolution in the fourth quarter, the client paid this amount to Covance, which will in turn be remitted to the tax authorities in the first quarter of 2014. 

The pro forma effective tax rate in the fourth quarter was 21.6%, down 670 basis points sequentially from the pro forma effective tax rate of 28.3% last quarter. The effective tax rate in the third quarter included a six month impact, or approximately 900 basis points, from the shift in accounting of the UK R&D credit. The fourth quarter effective tax rate included a benefit of approximately 220 basis points (contributing approximately $0.02 in earnings per share) attributable to the finalization of our 2013 pre-tax earnings mix, where a greater proportion of our earnings came from operations in tax jurisdictions with lower income tax rates. The 2013 full year pro forma effective tax rate was 22.9% and is expected to be approximately 24.5% in 2014.

The Company's investor conference call will be webcast on February 5 at 9:00 am ET. Management's commentary and presentation slides will be available through www.covance.com.

Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $2.4 billion and more than 12,000 employees located in over 60 countries. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at www.covance.com.

Statements contained in this press release, which are not historical facts, such as statements about prospective earnings, savings, revenue, operations, revenue and earnings growth and other financial results are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including the statements contained herein regarding anticipated trends in the Company's business are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, levels of industry research and development spending, the Company's ability to continue to attract and retain qualified personnel, the fixed price nature of contracts or the loss or delay of large studies, risks associated with acquisitions and investments, the Company's ability to increase order volume, the pace of translation of orders into revenue in late-stage development services, testing mix and geographic mix of kit receipts in central laboratories,  fluctuations in currency exchange rates, the realization of savings from the Company's announced restructuring actions, the cost and pace of completion of our information technology projects and the realization of benefits therefrom and other factors described in the Company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations.

Financial Exhibits Follow

 

 

COVANCE INC.












CONSOLIDATED INCOME STATEMENTS












FOR THE THREE MONTHS AND YEARS ENDED DECEMBER 31, 2013 AND 2012












(Dollars in thousands, except per share data)
























Three Months Ended December 31


Years Ended December 31




2013


2012


2013


2012




(UNAUDITED)
















Net revenues


$           623,094


$            562,180


$   2,402,313


$   2,180,621


Reimbursable out-of-pocket expenses


46,675


46,964


192,817


185,138


     Total revenues


669,769


609,144


2,595,130


2,365,759












Costs and expenses:










  Cost of revenue


436,857


395,841


1,692,173


1,570,223


  Reimbursable out-of-pocket expenses


46,675


46,964


192,817


185,138


  Selling, general and administrative


93,564


92,823


360,012


358,854


  Depreciation and amortization


32,845


30,423


127,917


117,708


  Impairment charges


4,877


-


4,877


17,959


        Total costs and expenses


614,818

(a)

566,051

(c)

2,377,796

(b)

2,249,882

(d)











Income from operations


54,951

(a)

43,093

(c)

217,334

(b)

115,877

(d)











Other expense (income), net:










  Interest expense, net


1,450


1,153


4,084


3,506


  Foreign exchange transaction loss, net


14


173


1,925


1,474


  Gain on sale of investments


-


-


(16,400)


(1,459)


  Impairment of equity investment


-


-


-


7,373


  Loss on sale of business


-


-


-


169


        Other expense (income), net


1,464


1,326


(10,391)

(b)

11,063

(d)











Income before taxes and equity investee earnings


53,487

(a)

41,767

(c)

227,725

(b)

104,814

(d)











Taxes on income


7,641

(a)

7,870

(c)

48,518

(b)

10,099

(d)











Equity investee earnings


-


-


-


17












Net income


$              45,846

(a)

$              33,897

(c)

$       179,207

(b)

$         94,732

(d)











Basic earnings per share


$                  0.83

(a)

$                   0.63

(c)

$             3.28

(b)

$             1.73

(d)











Weighted average shares outstanding - basic


55,021,244


53,698,334


54,648,533


54,844,641












Diluted earnings per share


$                  0.80

(a)

$                   0.61

(c)

$             3.15

(b)

$             1.68

(d)











Weighted average shares outstanding - diluted


57,205,147


55,197,968


56,899,013


56,290,010






















(a) Three months ended December 31, 2013 includes, as applicable, $4,874 in charges associated with restructuring and other cost reduction actions ($3,224 net of tax), $4,877 of asset impairment charges ($3,568 net of tax) and favorable income tax items totaling $3,035.

(b) Year ended December 31, 2013 includes, as applicable, $21,950 in charges associated with restructuring and other cost reduction actions ($14,576 net of tax), $16,400 gain on sale of investments ($10,654 net of tax), $4,877 of asset impairment charges ($3,568 net of tax) and favorable income tax items totaling $3,035.

(c) Three months ended December 31, 2012 includes, as applicable, $10,191 in restructuring costs ($6,968 net of tax), $3,613 favorable inventory adjustment ($2,502 net of tax) and $2,850 in losses at sites that were closed during the period ($1,966 net of tax).

(d) Year ended December 31, 2012 includes, as applicable, $33,930 in restructuring costs ($23,145 net of tax), $21,168 in inventory impairment charges and costs associated with the settlement of an inventory supply agreement ($14,645 net of tax), $17,959 of goodwill impairment charges ($17,959 net of tax), $7,373 of impairment of equity investment ($7,373 net of tax), $9,274 in losses at sites that were closed during the year ($6,533 net of tax), $1,459 gain on sale of investment ($945 net of tax) and favorable income tax items totaling $11,501.

























Excluding the impact of charges associated with restructuring and other cost reduction actions, impairment charges, gain on sale of investments, 

costs associated with the settlement of an inventory supply agreement, losses at sites that were closed during the period and favorable


tax items, as applicable:












Income from operations


$              64,702


$              52,521


$       244,161


$       198,208












Taxes on income


$              13,635


$              10,866


$         54,490


$         41,135












Net income 


$              49,603


$              40,329


$       183,662


$       151,941












Basic earnings per share


$                  0.90


$                   0.75


$             3.36


$             2.77












Diluted earnings per share


$                  0.87


$                   0.73


$             3.23


$             2.70












 

COVANCE INC.







CONSOLIDATED BALANCE SHEETS







DECEMBER 31, 2013 and DECEMBER 31, 2012







(Dollars in thousands)
















December 31


December 31




2013


2012







ASSETS





Current Assets:






Cash & cash equivalents


$        617,686


$       492,824


Short-term investments


111,359


-


Accounts receivable, net


331,815


339,558


Unbilled services


141,707


136,878


Inventory


48,257


49,270


Deferred income taxes


51,543


44,903


Income taxes receivable


-


3,642


Prepaid expenses and other current assets


201,621


167,629


    Total Current Assets


1,503,988


1,234,704







Property and equipment, net


913,612


891,319

Goodwill


109,820


109,820

Other assets


29,168


52,499


    Total Assets


$     2,556,588


$   2,288,342







LIABILITIES and STOCKHOLDERS' EQUITY





Current Liabilities:






Accounts payable


$          59,713


$         34,430


Accrued payroll and benefits


170,806


144,681


Accrued expenses and other current liabilities


153,808


127,686


Unearned revenue


240,398


255,776


Short-term debt 


-


320,000


Income taxes payable


7,952


-


    Total Current Liabilities


632,677


882,573







Long-term debt


250,000


-

Deferred income taxes


32,035


27,912

Other liabilities


76,630


70,665


    Total Liabilities


991,342


981,150







Stockholders' Equity:






Common stock


809


791


Paid-in capital


859,535


744,114


Retained earnings


1,779,833


1,600,626


Accumulated other comprehensive income


25,746


28,520


Treasury stock


(1,100,677)


(1,066,859)


    Total Stockholders' Equity


1,565,246


1,307,192


    Total Liabilities and Stockholders'  Equity


$     2,556,588


$   2,288,342







 

COVANCE INC.






CONSOLIDATED STATEMENTS OF CASH FLOWS






FOR THE YEARS ENDED DECEMBER 31, 2013 AND 2012






(Dollars in thousands)













Years Ended December 31








2013


2012

Cash flows from operating activities:





  Net income


$         179,207


$           94,732

  Adjustments to reconcile net income to net cash provided by





    operating activities:





    Depreciation and amortization


127,917


117,708

    Non-cash impairment charges


4,877


41,736

    Non-cash compensation expense associated with employee benefit





       and stock compensation plans


41,538


40,759

    Deferred income tax expense (benefit)


5,023


(8,404)

    Gain on sale of investments


(16,400)


(1,459)

    Loss on sale of business


-


169

    Loss on disposal of property and equipment


1,236


1,181

    Equity investee earnings


-


(17)

    Changes in operating assets and liabilities, net of business sold:





       Accounts receivable


7,743


(28,541)

       Unbilled services


(4,829)


(23,419)

       Inventory


(1,300)


10,918

       Accounts payable


25,283


(1,963)

       Accrued liabilities


50,885


8,205

       Unearned revenue


(15,378)


54,998

       Income taxes


14,315


(10,522)

       Other assets and liabilities, net


(14,467)


(35,920)

Net cash provided by operating activities


405,650


260,161






Cash flows from investing activities:





  Capital expenditures


(162,170)


(151,679)

  Purchase of short-term investments


(109,794)


-

  Proceeds from sale of investments


17,781


4,682

  Other, net


648


1,017

Net cash used in investing activities


(253,535)


(145,980)






Cash flows from financing activities:





  Net (repayments) borrowings under revolving credit facility


(320,000)


290,000

  Borrowings under long-term debt


250,000


-

  Stock issued under option plans


71,180


13,772

  Purchase of treasury stock


(33,818)


(323,773)

Net cash used in financing activities


(32,638)


(20,001)

Effect of exchange rate changes on cash


5,385


9,541

Net change in cash and cash equivalents


124,862


103,721






Cash and cash equivalents, beginning of period


492,824


389,103






Cash and cash equivalents, end of period


$         617,686


$         492,824






 

COVANCE INC.











GAAP to Pro Forma Reconciliation











Q4 2013











(Dollars in thousands, except per share data)











(UNAUDITED)














Adjustments




GAAP


 Restructuring
and Other Cost
Reduction
Activities (1)


Other
Items (2)


Income Tax
Items (3)


Pro Forma











Net revenues

$       623,094








$       623,094

Reimbursable out-of-pocket expenses

46,675








46,675

     Total revenues

669,769


-


-


-


669,769











Costs and expenses:










  Cost of revenue

436,857








436,857

  Reimbursable out-of-pocket expenses

46,675








46,675

  Selling, general and administrative

93,564


(4,456)






89,108

  Depreciation and amortization

32,845


(418)






32,427

  Impairment charges

4,877




(4,877)




-

        Total costs and expenses

614,818


(4,874)


(4,877)


-


605,067











Income from operations

54,951


4,874


4,877


-


64,702











Other expense, net:










  Interest expense, net

1,450








1,450

  Foreign exchange transaction loss, net

14








14

        Other expense, net

1,464


-


-


-


1,464











Income before taxes

53,487


4,874


4,877


-


63,238











Taxes on income

7,641


1,650


1,309


3,035


13,635











Net income 

$         45,846


$              3,224


$              3,568


$            (3,035)


$         49,603











Basic earnings per share

$             0.83


$                0.06


$                0.06


$              (0.06)


$             0.90











Weighted average shares outstanding - basic

55,021,244


55,021,244


55,021,244


55,021,244


55,021,244











Diluted earnings per share

$             0.80


$                0.06


$                0.06


$              (0.05)


$             0.87











Weighted average shares outstanding - diluted

57,205,147


57,205,147


57,205,147


57,205,147


57,205,147





















(1) Represents costs incurred to better align capacity to preclinical market demand and reduce overall cost structure.

(2) Represents asset impairment charges.

(3) Primarily represents favorable resolutions of income tax matters.











 

 

COVANCE INC.











GAAP to Pro Forma Reconciliation











Q4 2012











(Dollars in thousands, except per share data)











(UNAUDITED)














Adjustments



GAAP


 Restructuring
Activities (1)


Other
Items (2)


Operating
Results at
Sites Wound-
Down (3)


Pro Forma











Net revenues

$       562,180






$          (1,498)


$       560,682

Reimbursable out-of-pocket expenses

46,964








46,964

     Total revenues

609,144


-


-


(1,498)


607,646











Costs and expenses:










  Cost of revenue

395,841




3,613


(3,697)


395,757

  Reimbursable out-of-pocket expenses

46,964








46,964

  Selling, general and administrative

92,823


(9,013)




(117)


83,693

  Depreciation and amortization

30,423


(1,178)




(534)


28,711

        Total costs and expenses

566,051


(10,191)


3,613


(4,348)


555,125











Income from operations

43,093


10,191


(3,613)


2,850


52,521











Other expense, net:










  Interest expense, net

1,153








1,153

  Foreign exchange transaction loss, net

173








173

        Other expense, net

1,326


-


-


-


1,326











Income before taxes

41,767


10,191


(3,613)


2,850


51,195











Taxes on income

7,870


3,223


(1,111)


884


10,866











Net income 

$         33,897


$            6,968


$          (2,502)


$            1,966


$         40,329











Basic earnings per share

$             0.63


$              0.13


$             (0.05)


$              0.04


$             0.75











Weighted average shares outstanding - basic

53,698,334


53,698,334


53,698,334


53,698,334


53,698,334











Diluted earnings per share

$             0.61


$              0.13


$             (0.05)


$              0.04


$             0.73











Weighted average shares outstanding - diluted

55,197,968


55,197,968


55,197,968


55,197,968


55,197,968





















(1) Represents costs incurred to better align capacity to preclinical market demand and reduce overall cost structure.

(2) Reduction of inventory impairment based upon determination of actual impaired inventory.

(3) Represents results of operations at sites that were closed during the period.











 

COVANCE INC.











GAAP to Pro Forma Reconciliation











For the year ended December 31, 2013











(Dollars in thousands, except per share data)











(UNAUDITED)














Adjustments



GAAP


 Restructuring
and Other Cost
Reduction
Activities (1)


Other
Items (2)


Income Tax
Items (3)


Pro Forma











Net revenues

$   2,402,313








$   2,402,313

Reimbursable out-of-pocket expenses

192,817








192,817

     Total revenues

2,595,130


-


-


-


2,595,130











Costs and expenses:










  Cost of revenue

1,692,173








1,692,173

  Reimbursable out-of-pocket expenses

192,817








192,817

  Selling, general and administrative

360,012


(19,032)






340,980

  Depreciation and amortization

127,917


(2,918)






124,999

  Impairment charges

4,877




(4,877)




-

        Total costs and expenses

2,377,796


(21,950)


(4,877)


-


2,350,969











Income from operations

217,334


21,950


4,877


-


244,161











Other (income) expense, net:










  Interest expense, net

4,084








4,084

  Foreign exchange transaction loss, net

1,925








1,925

  Gain on sale of investments

(16,400)




16,400




-

        Other (income) expense, net

(10,391)


-


16,400


-


6,009











Income before taxes

227,725


21,950


(11,523)


-


238,152











Taxes on income

48,518


7,374


(4,437)


3,035


54,490











Net income 

$       179,207


$           14,576


$          (7,086)


$          (3,035)


$       183,662











Basic earnings per share

$             3.28


$                0.27


$             (0.13)


$             (0.06)


$             3.36











Weighted average shares outstanding - basic

54,648,533


54,648,533


54,648,533


54,648,533


54,648,533











Diluted earnings per share

$             3.15


$                0.26


$             (0.12)


$             (0.05)


$             3.23











Weighted average shares outstanding - diluted

56,899,013


56,899,013


56,899,013


56,899,013


56,899,013





















(1) Represents costs incurred to better align capacity to preclinical market demand and reduce overall cost structure.

(2) Consists of gain on sale of investments $16,400 and asset impairment charges ($4,877).

(3) Primarily represents favorable resolutions of income tax matters.











 

COVANCE INC.















GAAP to Pro Forma Reconciliation















For the year ended December 31, 2012















(Dollars in thousands, except per share data)















(UNAUDITED)


















Adjustments




GAAP


 Restructuring
Activities (1)


Other
Items (2)


Operating
Results at
Sites Wound-
Down (3)


Income Tax
Items (4)


Pro Forma















Net revenues

$   2,180,621






$          (8,754)




$   2,171,867


Reimbursable out-of-pocket expenses

185,138










185,138


     Total revenues

2,365,759


-


-


(8,754)


-


2,357,005















Costs and expenses:













  Cost of revenue

1,570,223




(21,168)


(15,180)




1,533,875


  Reimbursable out-of-pocket expenses

185,138










185,138


  Selling, general and administrative

358,854


(30,460)




(501)




327,893


  Depreciation and amortization

117,708


(3,470)




(2,347)




111,891


  Goodwill impairment charge

17,959




(17,959)






-


        Total costs and expenses

2,249,882


(33,930)


(39,127)


(18,028)


-


2,158,797















Income from operations

115,877


33,930


39,127


9,274


-


198,208















Other expense, net:













  Interest expense, net

3,506










3,506


  Foreign exchange transaction loss, net

1,474










1,474


  Impairment of equity investment

7,373




(7,373)






-


  Gain on sale of investment

(1,459)




1,459






-


  Loss on sale of business

169










169


        Other expense, net

11,063


-


(5,914)


-


-


5,149















Income before taxes and equity investee earnings

104,814


33,930


45,041


9,274


-


193,059















Taxes on income

10,099


10,785


6,009


2,741


11,501


41,135















Equity investee earnings

17










17















Net income 

$         94,732


$          23,145


$          39,032


$            6,533


$        (11,501)


$       151,941















Basic earnings per share

$             1.73


$              0.42


$              0.71


$              0.12


$             (0.21)


$             2.77















Weighted average shares outstanding - basic

54,844,641


54,844,641


54,844,641


54,844,641


54,844,641


54,844,641















Diluted earnings per share

$             1.68


$              0.41


$              0.69


$              0.12


$             (0.20)


$             2.70















Weighted average shares outstanding - diluted

56,290,010


56,290,010


56,290,010


56,290,010


56,290,010


56,290,010




























(1) Represents costs incurred to better align capacity to preclinical market demand and reduce overall cost structure.

(2) Consists of inventory impairment and costs associated with the settlement of an inventory supply agreement ($21,168), goodwill impairment ($17,959), impairment of equity investment ($7,373) and a gain on the sale of an investment $1,459.



(3) Represents results of operations at sites that were closed during the period.


(4) Primarily represents favorable resolutions of income tax matters.















 

SOURCE Covance Inc.



RELATED LINKS
http://www.covance.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.